



**AUSTRALIA BIOTECH  
INVEST & PARTNERING 2018**  
Connecting capital with innovation

Tuesday 30 October  
Sofitel Melbourne on Collins  
[ausbiotechinvestment.com.au](http://ausbiotechinvestment.com.au)

#AusBioInv



## NeuroScientific

BIOPHARMACEUTICALS

### Company profile

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) is a drug development company focused on developing novel peptide-based drugs, called Emtins, which have the potential to treat neurodegenerative conditions. The company's lead drug candidate, called EmtinB is most advanced as a treatment for Alzheimer's disease.

EmtinB has been shown to induce the survival and regrowth of neurons through binding to specific receptors expressed by neuronal cells. The peptide offers a novel therapeutic treatment pathway for neurodegenerative diseases that are currently without effective treatment options. In parallel with the Alzheimer's disease development program, EmtinB is being developed as a treatment for degenerative conditions of the optic nerve via a strategic partnership with the esteemed Lions Eye Institute.

### Speaker Profile

Mr Matt Liddelov is an experienced professional in the commercialisation of biotechnology, medical devices and pharmaceuticals. Mr Liddelov has been involved in a number of successful start-up companies and was an employee of multi-national pharmaceutical company AstraZeneca for many years.

